Table 1

Clinical and demographic characteristics of patients included in cohorts 1 and 2

CharacteristicsActive* CD without anti-TNFαActive* CD with anti-TNFα (non-responders)Inactive* CD with anti-TNFα (responders)Non-IBD Controls
Cohort 1: Microarray analysis
Number105717
Gender (M/F)7/34/14/39/8
Age (years)34 (21–68)31 (20–48)34 (21–37)50 (29–55)
Disease duration (years)6 (0.7–18.8)12 (0.94–27.8)5.6 (0.69–8.9)
Age at diagnosis (A1/A2/A3)†‡0/7/30/3/20/7/0
Location (L1/L2/L3/L4)§‡0/6/4/00/4/1/00/3/4/0
Behaviour (B1/B2/B3) ¶‡8/1/13/1/16/0/1
Perianal disease (yes/no)‡1/91/42/5
Type of anti-TNFα (infliximab/adalimumab)2/30/7
Concomitant azathioprine (yes/no)6/42/34/3
Past anti-TNFα exposure (yes/no)2/82/31/6
Biopsy location**3/1/3/2/11/1/1/2/02/2/3/0/07/2/1/5/0/2
CDAI190.5 (45–440)165.5 (142–189)51 (4–149)††
CRP (mg/dL)2.9 (0.5–12.2)0.5 (0.1–13.3)0.04 (0.01–2.5)††
CDEIS14.2 (9–23)12.5 (5.4–20.5)0.4 (0–4.4)††
Cohort 2: Real-time RT-PCR
Number161077
Gender (M/F)8/85/53/43/4
Age (years)33 (19–59)31.5 (20–68)47 (20–67)31 (26–49)
Disease duration (years)3.8 (0–22.5)4.5 (0.5–19)3.1 (0–32)
Age at diagnosis (A1/A2/A3)†‡0/13/30/7/30/2/5
Location (L1/L2/L3/L4)§‡0/8/8/00/7/3/00/6/1/0
Behaviour (B1/B2/B3) ¶‡14/2/09/1/06/1/0
Perianal disease (yes/no)‡4/122/84/3
Type of anti-TNFα (infliximab/adalimumab)4/62/5
Concomitant azathioprine (yes/no)10/66/42/5
Past anti-TNFα exposure (yes/no)0/162/81/6
Biopsy location**6/2/1/4/2/14/0/3/3/0/00/1/2/0/2/20/1/0/2/0/4
CDAI199 (79–329)88 (42–216)††46.5 (5–104)††
CRP (mg/dL)4.6 (0.01–23.7)0.33 (0.02–8.9)0.13 (0.01–0.8)††
CDEIS13.6 (5.4–36.4)10 (5.8–20)1.75 (0–5.3)††
  • Numerical variables are described as median and numeric range (min, max) and categorical variables as absolute frequencies.

  • *Endoscopic activity.

  • †Age <16 years/17–40 years/>40 years.

  • ‡Montreal Classification.

  • §Ileal/colonic/ileocolonic/isolated upper disease.

  • ¶Inflammatory/structuring/penetrating.

  • **Ascending colon/transverse colon/descending colon/sigmoid/rectum/non-informed colonic segment.

  • ††p<0.005 compared with active CD without anti-TNFα.

  • CD, Crohn's disease; CDAI, CD Activity Index; CDEIS, CD Endoscopic Index of Severity; CRP, C-reactive protein; Non-IBD; non-inflammatory bowel disease; TNF, tumour necrosis factor.